UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K/A

Amendment No. 1

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended June 30, 2021 Commission file number: 001-15317

ResMed Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

98-0152841

(IRS Employer Identification No.)

9001 Spectrum Center Blvd. San Diego, CA 92123 United States of America (Address of principal executive offices)

(858) 836-5000

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.004 per share	RMD	New York Stock Exchange
Se	ecurities registered pursuant to Section 12(g) of the Act None	
Indicate by check mark if the registrant is a well-known	seasoned issuer, as defined in Rule 405 of the Securities Act.	Yes ☒ No ☐
Indicate by check mark if the registrant is not required to	o file reports pursuant to Section 13 or 15(d) of the Act. Yes	; □ No 🗵
	ed all reports required to be filed by Section 13 or 15(d) of the registrant was required to file such reports), and (2) has been section 15 or 15(d) of the registrant was required to file such reports.	
,	tted electronically every Interactive Data File required to be so ths (or for such shorter period that the registrant was required	1
	accelerated filer, an accelerated filer, a non-accelerated filer, a ed filer," "accelerated filer," "smaller reporting company," and	
Large Accelerated Filer Non-accelerated Filer Emerging Growth Company	Accelerated Filer Smaller Reporting Company	
If an emerging growth company, indicate by check mark financial accounting standards provided pursuant to Sect	if the registrant has elected not to use the extended transition tion $13(a)$ of the Exchange Act. \Box	period for complying with any new or revised
	report on and attestation to its management's assessment of ti-Oxley Act (15 U.S.C. 7262(b)) by the registered public account	
Indicate by check mark whether the registrant is a shell of	company (as defined in Rule 12b-2 of the Exchange Act). Y	es No 🗵
	g common equity held by non-affiliates of registrant as of Dec er), computed by reference to the closing sale price of such sto 0% stockholders of registrant are considered affiliates.	

At August 12, 2021, registrant had 145,681,186 shares of Common Stock, \$0.004 par value, issued and outstanding. This number excludes 41,836,234 shares held by the registrant as treasury shares.

Portions of the registrant's definitive Proxy Statement to be delivered to stockholders in connection with the registrant's 2021 Annual Meeting of Stockholders, to be filed subsequent to the date hereof, are incorporated by reference into Part III of this report.

EXPLANATORY NOTE

This Amendment No. 1 on Form 10-K/A (this "Amendment") amends the Annual Report on Form 10-K of ResMed Inc. for the fiscal year ended June 30, 2021, as filed with the Securities and Exchange Commission on August 16, 2021 (the "Original Filing"). This amendment is being filed for the sole purpose of amending and restating in its entirety "Item 15. Exhibits and Consolidated Financial Statement Schedules" under Part IV of the Original Filing to correct hyperlinks to exhibits that were filed in conjunction with the Original Filing. Due to a technical error, these hyperlinks were not functional in our original August 16, 2021 filing. Except as noted above, this Form 10-K/A does not update or modify any disclosures in or reflect any events occurring after the filing of the Original Filing. Accordingly, this Form 10-K/A should be read in conjunction with the Original Filing.

In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), new certifications by the Company's principal executive officer and principal financial officer are filed herewith as exhibits to this Amendment No. 1 pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act. As no financial statements have been included in this Amendment No. 1 and it does not contain or amend any disclosure with respect to Items 307 or 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. The Company is not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) as no financial statements are being filed with this Amendment.

PART IV Item 15

PART IV

ITEM 15 EXHIBITS AND CONSOLIDATED FINANCIAL STATEMENT SCHEDULES

The following documents are filed as part of this report:

(a) Consolidated Financial Statements and Schedules – The index to our consolidated financial statements and schedules are set forth in the "Index to Consolidated Financial Statements" under Item 8 of this report.

- (b) Exhibit Lists
- 2.1 Agreement and Plan of Merger, dated November 5, 2018, by and among ResMed Operations Inc., Evolved Sub, Inc.,
 ResMed Inc., OPEL GI Holdings Limited, in its capacity as the agent acting on behalf of the holders of common stock of
 MatrixCare Holdings, Inc., and MatrixCare Holdings, Inc. (Incorporated by reference to Exhibit 2.1 to the Registrant's
 Report on Form 8-K filed on November 8, 2018)
- 3.1 <u>First Restated Certificate of Incorporation of ResMed Inc., as amended.</u> (Incorporated by reference to Exhibit 3.1 to the Registrant's Report on Form 10-Q for the quarter ended September 30, 2013)
- 3.2 <u>Sixth Amended and Restated Bylaws of ResMed Inc.</u> (Incorporated by reference to Exhibit 3.1 to the Registrant's Report on Form 8-K filed on February 26, 2020)
- 4.1 Form of certificate evidencing shares of Common Stock. (Incorporated by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-1 (No. 33-91094) declared effective on June 1, 1995)
- 4.2 <u>Description of ResMed Inc.'s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934</u> (Incorporated by reference to Exhibit 4.2 to the Registrant's Report on Form 10-K filed on August 13, 2020)
- 10.1* Form of Indemnification Agreements for our directors and officers. (Incorporated by reference to Exhibit 10.1 to the Registrant's Report on Form 8-K filed on June 24, 2009)
- 10.2* Form of Access Agreement for directors. (Incorporated by reference to Exhibit 10.2 to the Registrant's Report on Form 8-K filed on June 24, 2009)
- 10.3* <u>Updated Form of Executive Agreement.</u> (Incorporated by reference to Exhibit 99.1 to the Registrant's Report on Form 8-K filed on July 2, 2012)
- 10.4* <u>Amendment and Restatement to the ResMed Inc. 2009 Incentive Award Plan.</u> (Incorporated by reference to Appendix B of ResMed Inc.'s Proxy Statement filed with the Securities and Exchange Commission on September 25, 2017)
- 10.5* ResMed Inc. Deferred Compensation Plan. (Incorporated by reference to Exhibit 4.4 to the Registrant's Report on Form S-8 filed on May 21, 2021)
- 10.6* Form of Restricted Stock Unit Award Agreement for Executive Officers. (Incorporated by reference to Exhibit 10.1 to the Registrant's Report on Form 10-O for the quarter ended September 30, 2011, filed on November 3, 2011)
- 10.7* Form of Restricted Stock Unit Award Agreement for Directors. (Incorporated by reference to Exhibit 10.2 to the Registrant's Report on Form 10-Q for the quarter ended September 30, 2011, filed on November 3, 2011)
- 10.8* Form of Stock Option Grant for Executive Officers. (Incorporated by reference to Exhibit 10.3 to the Registrant's Report on Form 10-Q for the quarter ended September 30, 2011, filed on November 3, 2011)
- 10.9* Form of Stock Option Grant for Directors. (Incorporated by reference to Exhibit 10.4 to the Registrant's Report on Form 10-Q for the quarter ended September 30, 2011, filed on November 3, 2011)
- 10.10*† Form of Performance-Based Restricted Stock Unit Award Agreement for Executive Officers.
- 10.11*† Form of Executive Restricted Stock Unit Award Agreement for Executive Officers.
- Amended and Restated Credit Agreement dated as of April 17, 2018, by and among ResMed Inc., as borrower, each of the lenders identified on the Revolving Credit Agreement's signature pages as a lender, MUFG Union Bank, N.A., as administrative agent, joint lead arranger, joint book runner, swing line lender and l/c issuer, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner. (Incorporated by reference to Exhibit 10.1 to the Registrant's Report on Form 8-K filed on April 19, 2018)
- 10.13 Amended and Restated Unconditional Guaranty dated as of April 17, 2018, by each of the guarantors identified on the Revolving Facility Guaranty's signature pages as a guarantor, in favor of MUFG Union Bank, N.A., in its capacity as administrative agent under the Revolving Credit Agreement. (Incorporated by reference to Exhibit 10.2 to the Registrant's Report on Form 8-K filed on April 19, 2018)
- 10.14 Syndicated Facility Agreement, dated as of April 17, 2018, by and among ResMed Limited, as borrower, the other parties party thereto, each of the lenders identified on the Term Credit Agreement's signature pages as a lender, MUFG Union Bank, N.A., as administrative agent, joint lead arranger and joint book runner, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner. (Incorporated by reference to Exhibit 10.3 to the Registrant's Report on Form 8-K filed on April 19, 2018)

PART IV Item 15

10.15 <u>Unconditional Guaranty dated as of April 17, 2018, by each of the guarantors identified on the Term Facility Guaranty's signature pages as a guarantor, in favor of MUFG Union Bank, N.A., in its capacity as administrative agent under the Term Credit Agreement. (Incorporated by reference to Exhibit 10.4 to the Registrant's Report on Form 8-K filed on April 19, 2018)</u>

- 10.16 First Amendment to Amended and Restated Credit Agreement, dated November 5, 2018, by and among ResMed Inc., as borrower, each of the lenders identified in the First Amendment, MUFG Union Bank, N.A., as administrative agent, joint lead arranger, joint book runner, swing line lender and letter of credit issuer, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner. (Incorporated by reference to Exhibit 10.1 to the Registrant's Report on Form 8-K filed on November 8, 2018)
- 10.17 <u>The ResMed Inc. 2018 Employee Stock Purchase Plan.</u> (Incorporated by reference to Appendix B of ResMed Inc.'s Proxy Statement filed with the Securities and Exchange Commission on October 3, 2018.)
- 10.18 Note Purchase Agreement, dated July 10, 2019 by and among ResMed Inc. and the purchasers party to that agreement (including form of 3.24% Series A Senior Note due 2026, form of Series B 3.45% Senior Note due 2029, and form of Subsidiary Guaranty Agreement). (Incorporated by reference to Exhibit 10.1 to the Registrant's Report on Form 8-K filed on July 15, 2019)
- 21.1† Subsidiaries of the Registrant.
- 23.1† Consent of Independent Registered Public Accounting Firm.
- 31.1† Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002.
- 31.2† Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002.
- 31.3‡ Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002.
- 31.4‡ Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002.
- 32.1† Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- The following materials from ResMed Inc.'s Annual Report on Form 10-K for the fiscal year ended June 30, 2021 formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Income, (iii) the Consolidated Statements of Stockholders' Equity and Comprehensive Income, (iv) the Consolidated Statements of Cash Flows and (v) related notes.
 - * Management contract or compensatory plan or arrangement
 - † Previously filed with the Original Filing.
 - ‡ Filed herewith.

PART IV Signatures

SIGNATURES

Under the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized persons below.

DATED August 19, 2021

ResMed Inc.

/s/ MICHAEL J. FARRELL

Michael J. Farrell Chief executive officer (Principal Executive Officer)